Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

NCT04506619 is registered in ClinicalTrials.gov with Oak Hill Bio Ltd as lead sponsor.

NCT NCT04506619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04506619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Lead sponsor
Oak Hill Bio Ltd
Phase
Observational
Overall status
Terminated
Start date
September 9, 2020
Completion date
August 5, 2022
Enrollment
26 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia, chronic lung disease of prematurity, intraventricular hemorrhage, retinopathy of prematurity (rop)